Biohaven’s treatment for Lou Gehrig’s disease fails to win FDA nod
FILE PHOTO: The logo for Biohaven Pharmaceutical Holding Company is displayed on a screen during the company’s IPO on the floor of the New York Stock Exchange (NYSE) in New…
Biohaven plunges as investors pit migraine data against Allergan’s drug
(Reuters) – Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from…